A Phase 1 Safety and Efficacy Study of IS-002 Injection in Patients Undergoing Robotic Prostatectomy

Open to males ages 18-75

• Subject is between the ages of 18 and 75.
• Subject has a confirmed adenocarcinoma by histology of the prostate.
• Subject has CAPRA > 6, or T3 a or b disease on imaging (TRUS and/or MRI), or regional lymphadenopathy suspicious for nodal metastases
• Subject is scheduled to undergo robotic prostatectomy with extended pelvic lymph node dissection (ePLND) using an da Vinci® X/Xi Surgical System with Firefly® Fluorescent Imaging.
• Subject is willing and able to provide informed consent
• Subject is considered capable of complying with study procedures and of understanding a written informed consent document.
• Subject must be treatment naïve (not having received neo-adjuvant therapy, radiation therapy, hormonal therapy, androgen deprivation therapy within the last 4 months excluding Finasteride, Dutasteride, or other 5 alpha reductase inhibitors, or focal ablation techniques)

• Subject has known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection
• Subject is currently participating in and receiving study therapy or has participated in a study of an investigational agent within the past 6 months; is receiving study therapy or is involved in a significant risk investigational device study within the past 6 months
• Subject has any other condition or personal circumstance that, in the judgment of the Investigator, might interfere with the collection of complete quality data or represents an unacceptable safety profile
• Subject has a known history of bone metastasis documented on the basis of bone scans and/or biopsy
• Subject has a known history of acute or chronic liver or kidney disease